Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from... Cardiol Ther (2015) 4:83–93 DOI 10.1007/s40119-014-0032-9 CASE REPORT Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl • • Amir Hassan Nadeem Tajuddin Ali Shaikh To view enhanced content go to www.cardiologytherapy-open.com Received: November 18, 2014 / Published online: December 17, 2014 The Author(s) 2014. This article is published with open access at Springerlink.com Methods: This was a retrospective analysis of ABSTRACT records from a private endocrinology practice of Introduction: Patients with diabetes and patients who received omega-3-acid ethyl esters prediabetes are at increased risk of (OM3EE) (4 g/day) and were subsequently dyslipidemia and cardiovascular disease. To switched to icosapent ethyl (IPE; 4 g/day) due reduce this risk, statins and additional to the potential of OM3EE to raise LDL-C and/or therapies may be considered. Omega-3 fatty cause gastrointestinal upset. Patient records acids offer an option to reduce triglycerides were analyzed for LDL-C, TG, total cholesterol (TG) and potentially improve other lipid (TC), high-density lipoprotein cholesterol parameters, although products that contain (HDL-C), and non-HDL-C measured before and docosahexaenoic acid (DHA) may increase after the switch to IPE. low-density lipoprotein cholesterol (LDL-C) Results: The records of ten patients met the while http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/retrospective-case-series-of-patients-with-diabetes-or-prediabetes-who-AIq7vbDBE0
Publisher
Springer Journals
Copyright
Copyright © 2014 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-014-0032-9
pmid
25515964
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2015) 4:83–93 DOI 10.1007/s40119-014-0032-9 CASE REPORT Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl • • Amir Hassan Nadeem Tajuddin Ali Shaikh To view enhanced content go to www.cardiologytherapy-open.com Received: November 18, 2014 / Published online: December 17, 2014 The Author(s) 2014. This article is published with open access at Springerlink.com Methods: This was a retrospective analysis of ABSTRACT records from a private endocrinology practice of Introduction: Patients with diabetes and patients who received omega-3-acid ethyl esters prediabetes are at increased risk of (OM3EE) (4 g/day) and were subsequently dyslipidemia and cardiovascular disease. To switched to icosapent ethyl (IPE; 4 g/day) due reduce this risk, statins and additional to the potential of OM3EE to raise LDL-C and/or therapies may be considered. Omega-3 fatty cause gastrointestinal upset. Patient records acids offer an option to reduce triglycerides were analyzed for LDL-C, TG, total cholesterol (TG) and potentially improve other lipid (TC), high-density lipoprotein cholesterol parameters, although products that contain (HDL-C), and non-HDL-C measured before and docosahexaenoic acid (DHA) may increase after the switch to IPE. low-density lipoprotein cholesterol (LDL-C) Results: The records of ten patients met the while

Journal

Cardiology and Therapy – Springer Journals

Published: Dec 17, 2014

References

  • Standards of medical care in diabetes–2014
  • American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis
    Jellinger, PS; Smith, DA; Mehta, AE; Ganda, O; Handelsman, Y; Rodbard, HW
  • The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis
    Murad, MH; Hazem, A; Coto-Yglesias, F; Dzyubak, S; Gupta, S; Bancos, I
  • Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
    Miselli, MA; Nora, ED; Passaro, A; Tomasi, F; Zuliani, G
  • Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association
    Miller, M; Stone, NJ; Ballantyne, C; Bittner, V; Criqui, MH; Ginsberg, HN
  • Residual macrovascular risk in 2013: what have we learned?
    Fruchart, JC; Davignon, J; Hermans, MP; Al-Rubeaan, K; Amarenco, P; Assmann, G
  • The Johns Hopkins textbook of dyslipidemia
    Bays, H
  • Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events
    Mozaffarian, D; Wu, JH
  • Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis
    Wei, MY; Jacobson, TA
  • Safety and efficacy of Omacor in severe hypertriglyceridemia
    Harris, WS; Ginsberg, HN; Arunakul, N; Shachter, NS; Windsor, SL; Adams, M
  • Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) trial]
    Bays, HE; Ballantyne, CM; Kastelein, JJ; Isaacsohn, JL; Braeckman, RA; Soni, PN
  • Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
    Ballantyne, CM; Bays, HE; Kastelein, JJ; Stein, E; Isaacsohn, JL; Braeckman, RA
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
  • National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary
    Jacobson, TA; Ito, MK; Maki, KC; Orringer, CE; Bays, HE; Jones, PH
  • Potential benefits of icosapent ethyl on the lipid profile: case studies
    Hilleman, DE; Malesker, MA
  • A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients
    Castaldo, RS
  • Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline
    Berglund, L; Brunzell, JD; Goldberg, AC; Goldberg, IJ; Sacks, F; Murad, MH
  • Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
    Friedewald, WT; Levy, RI; Fredrickson, DS
  • Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
    Brinton, EA; Ballantyne, CM; Bays, HE; Kastelein, JJ; Braeckman, RA; Soni, PN
  • Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
    Balk, EM; Lichtenstein, AH; Chung, M; Kupelnick, B; Chew, P; Lau, J
  • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico
  • n-3 fatty acids and cardiovascular events after myocardial infarction
    Kromhout, D; Giltay, EJ; Geleijnse, JM
  • n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
  • OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction
    Rauch, B; Schiele, R; Schneider, S; Diller, F; Victor, N; Gohlke, H
  • Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
    Yokoyama, M; Origasa, H; Matsuzaki, M; Matsuzawa, Y; Saito, Y; Ishikawa, Y
  • Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
    Saito, Y; Yokoyama, M; Origasa, H; Matsuzaki, M; Matsuzawa, Y; Ishikawa, Y
  • Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial
    Mozaffarian, D; Marchioli, R; Macchia, A; Silletta, MG; Ferrazzi, P; Gardner, TJ
  • Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis
    Larsson, SC; Orsini, N; Wolk, A
  • Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease
    Matsuzaki, M; Yokoyama, M; Saito, Y; Origasa, H; Ishikawa, Y; Oikawa, S
  • Loss-of-function mutations in APOC3, triglycerides, and coronary disease
  • Loss-of-function mutations in APOC3 and risk of ischemic vascular disease
    Jorgensen, AB; Frikke-Schmidt, R; Nordestgaard, BG; Tybjaerg-Hansen, A